The global urothelial cancer drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the existence of a strong pipeline, availability of novel drugs, and growing incidence of urothelial cancer among the rising geriatric population. Additionally the changed lifestyle and rising public awareness are major driving factors for the market growth.
Request Free Sample Report Here
A type of tumor formation in the bladder is called as urothelial carcinoma and is also known as transitional cell carcinoma. It is a type of malignant neoplasm arising from urothelium that can affect other parts of the body without proper treatment and therapy. The urothelium is inner lining of the urethra, bladder, and ureters. The cancer type is broadly classified into three classes: the early stage or non-muscle invasive bladder cancer (NMIBC), the mid-stage or muscle-invasive bladder cancer disease (MIBC), and the late-stage called metastatic disease. As per a global health report, about 70% of patients are of NMIBC, 20% are of the MIBC, and 10% at the late stage.
As per Globocan 2020, the disease ranks as 10th most common malignancy disease worldwide, with around 2.4 million cases and 419,000 newly detected patients recorded every year. Bladder urothelial carcinoma is responsible for nearly 90% of all urinary cancer patients. According to the report of the International Agency for Research on Cancer (IARC), 60% of all bladder cancer cases are witnessed in developed countries such as the US and some countries of Europe while Belgium tops the list with the highest number of bladder cancer cases.
Market Trends, Drivers, Restraints, and Opportunities
- Surging numbers of cases suffering from urothelial cancer and large recurrence rate of patients among geriatric population across the world are major driving factors for the market.
- Increasing awareness among the population and initiatives by government and non-government organizations for early diagnosis of cancer are propelling the market growth.
- High number of new drug approvals in the field along with large funding for the research and development activities presents a major factor for the overall market growth.
- Availability of significant number of generic drugs in the market and high expenditure on R&D are proving to be major restraints to the market.
- Rising concerns related to the side effects associated with chemotherapy is a challenge that can hamper the market expansion in the coming future.
- Advanced technology for the development of new drugs is offering great opportunities for the market in the near future.
Market Segment Insights
Chemotherapy segment is expected to grow at a considerable pace
Based on treatments, the global urothelial cancer drugs market is bifurcated into chemotherapy and immunotherapy. The chemotherapy segment is expected to grow at a considerable pace during the forecast period considering the factors that the chemotherapy can be used alone as well as in the combination therapy when needed. Chemotherapy is used to reduce or stop the development of cancer cells and is the most commonly adopted form of treatment.
North America is anticipated to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to dominate the market during the forecast period owing to the factors including availability of large targeted patients, increased drug approvals, adoption of novel therapeutics, and high funding in the region.
Competitive Landscape
Key players competing in the global urothelial cancer drugs market are Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; GlaxoSmithKline plc.; Genentech; Bristol-Myers Squibb Co.; Sanofi; F. Hoffmann-La Roche Ltd; Novartis AG; Merck KGaA; Eli Lilly and Co.; AstraZeneca; Exelixis, Inc.; Johnson & Johnson Services, Inc.; Immunomedics; UroGen Pharma, Inc.; Astellas Pharma US, Inc.; Janssen Biotech, Inc.; Sitka Biopharma; and Sesen Bio.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: sales@growthmarketreports.com
Web: https://growthmarketreports.com
